The World Health Organization (WHO) already predicted, according to the pace of diagnosis and the characteristics of the disease that in 2020 depression would become the most disabling disease in the world. Currently, depression is responsible for the reduction of up to ten years of life expectancy, is the main cause of disability, has high rates of morbidity and mortality, being responsible, therefore, for an extremely negative direct impact on the quality of life of more than 322 million of people around the world, confirming and exceeding WHO estimates. Facing a disease with unfavourable outcomes, treatment becomes essential to maintain the patients' quality of life. However, a third of individuals diagnosed with depression do not respond adequately to the first-choice treatments, including monoamine reuptake inhibitors. In addition, these drugs take between three to seven weeks to start their antidepressant effects and up to 12 weeks to achieve maximum effect, as well having side effects in most users. In many situations, the combination of two or more of these drugs is not able to cease the patient's depressive symptoms, raising him to the diagnosis of treatmentresistant depression [4]. In this sense, the need for more effective treatments, with a faster onset of action, better dosage, and fewer side effects has increased in recent years and new therapeutic approaches for depressed patients have emerged aiming to reduce the unfavourable outcomes resulting from this pathology.